BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31381964)

  • 21. Oncolytic measles viruses for cancer therapy.
    Nakamura T; Russell SJ
    Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuated oncolytic measles virus strains as cancer therapeutics.
    Msaouel P; Iankov ID; Dispenzieri A; Galanis E
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.
    Weiland T; Lampe J; Essmann F; Venturelli S; Berger A; Bossow S; Berchtold S; Schulze-Osthoff K; Lauer UM; Bitzer M
    Int J Cancer; 2014 Jan; 134(1):235-43. PubMed ID: 23797800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary resistance phenomena to oncolytic measles vaccine viruses.
    Noll M; Berchtold S; Lampe J; Malek NP; Bitzer M; Lauer UM
    Int J Oncol; 2013 Jul; 43(1):103-12. PubMed ID: 23612727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic measles virus strains as novel anticancer agents.
    Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
    Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial overview: Oncolytic viruses--replicating virus therapeutics for the treatment of cancer.
    Bell JC; McFadden G
    Curr Opin Virol; 2015 Aug; 13():viii-ix. PubMed ID: 26260227
    [No Abstract]   [Full Text] [Related]  

  • 28. Oncolytic measles virus strains in the treatment of gliomas.
    Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
    Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
    Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Jung MY; Offord CP; Ennis MK; Kemler I; Neuhauser C; Dingli D
    Cancer Res; 2018 Oct; 78(20):5992-6000. PubMed ID: 30115692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy.
    Kim EJ; Yoo JY; Choi YH; Ahn KJ; Lee JD; Yun CO; Yun M
    Yonsei Med J; 2008 Oct; 49(5):811-8. PubMed ID: 18972602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mathematical model of oncolytic virotherapy with time delay.
    Wang ZZ; Guo ZM; Smith H
    Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measles as a potential oncolytic virus.
    Fielding AK
    Rev Med Virol; 2005; 15(2):135-42. PubMed ID: 15546127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors.
    Zimmermann M; Armeanu-Ebinger S; Bossow S; Lampe J; Smirnow I; Schenk A; Lange S; Weiss TS; Neubert W; Lauer UM; Bitzer M
    PLoS One; 2014; 9(3):e90508. PubMed ID: 24598703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering and combining oncolytic measles virus for cancer therapy.
    Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G
    Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.